Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp

Ironwood Pharmaceuticals (NASDAQ:IRWD) had its target price lifted by Citizens Jmp from $8.00 to $10.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a market outperform rating on the biotechnology company’s stock.

A number of other analysts also recently commented on the company. Craig Hallum upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Wells Fargo & Company raised their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.93.

Ironwood Pharmaceuticals Trading Up 8.9%

IRWD opened at $3.66 on Thursday. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.78. The firm has a 50 day moving average of $4.28 and a two-hundred day moving average of $2.80. The firm has a market capitalization of $595.41 million, a PE ratio of 28.15 and a beta of 0.17.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). The business had revenue of $47.71 million for the quarter, compared to analysts’ expectations of $86.10 million. Ironwood Pharmaceuticals had a negative return on equity of 13.72% and a net margin of 8.11%. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in IRWD. Integrated Wealth Concepts LLC grew its position in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the period. Focus Partners Advisor Solutions LLC lifted its stake in Ironwood Pharmaceuticals by 284.6% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 29,409 shares in the last quarter. LSV Asset Management acquired a new stake in Ironwood Pharmaceuticals in the 4th quarter worth about $30,000. Captrust Financial Advisors purchased a new stake in Ironwood Pharmaceuticals during the 2nd quarter worth approximately $32,000. Finally, Jump Financial LLC purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter worth approximately $34,000.

Ironwood Pharmaceuticals News Summary

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Management raised FY‑2026 revenue guidance to $450–$475 million and reiterated a strong outlook; LINZESS showed continued demand growth (11% EUTRx), which supports the higher top‑line guide. Ironwood Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst upgrade from Citizens JMP: price target raised to $10 with a “market outperform” rating — a significant bullish signal that can attract buyers and supports the stock’s rally. Benzinga
• Positive Sentiment: The company reiterated 2025 results achievement and provided investor materials (slide deck) and the conference‑call transcript, giving investors more transparency into drivers of the guide and product performance. Slide Deck
• Neutral Sentiment: Full Q4 earnings call transcript and presentation are available for review; these provide detail on cost structure, guidance assumptions and timing that investors will parse for clarity. Earnings Call Transcript
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.01) vs. $0.02 expected and revenue of $47.7M vs. ~$86.1M consensus (revenue down ~47% YoY). The sizable miss and year‑over‑year revenue decline are the primary near‑term negative catalysts. Zacks: Q4 Earnings and Revenues Fall Shy
• Negative Sentiment: A Seeking Alpha piece downgraded the stock after reporting a pipeline setback and an extended timeline for Apraglutide, raising execution and timing risk for future growth catalysts. Seeking Alpha: Downgrading On Pipeline Setback

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.